Residual IDH1-Mutant Tumor Cell Quantification Study
NCT: NCT07219199 · NOT_YET_RECRUITING
Brief Summary
This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.
Frequently Asked Questions
What is Residual IDH1-Mutant Tumor Cell Quantification Study?
Residual IDH1-Mutant Tumor Cell Quantification Study is a clinical trial registered under NCT07219199. Current status: NOT_YET_RECRUITING.
What is the status of NCT07219199?
The current status of NCT07219199 (Residual IDH1-Mutant Tumor Cell Quantification Study) is: NOT_YET_RECRUITING.
When did Residual IDH1-Mutant Tumor Cell Quantification Study start?
Residual IDH1-Mutant Tumor Cell Quantification Study started on 2027-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.